DGAP-Adhoc

Epigenomics AG issues new shares by way of private placement

Epigenomics AG / Key word(s): Capital Increase

24.05.2016 17:56

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Ad Hoc Announcement Pursuant to §15 WpHG (German Securities Trading Act)

Epigenomics AG issues new shares by way of private placement

Not for distribution in the United States of America

Berlin, Germany, May 24, 2016 - Epigenomics AG, Berlin, Germany (Frankfurt
Prime Standard: ECX, ISIN: DE0000A11QW50), announces that the Company is
raising around EUR 6.8 million of gross proceeds in a share capital
increase.

The Executive Board of Epigenomics AG, with approval of the Supervisory
Board, has today resolved on the increase of the Company's share capital in
the amount of EUR 1,436,000.00 by issuing 1,436,000 new registered shares
of the Company from the Authorized Capital 2015/I against contribution in
cash. The issue price has been set at EUR 4.76 per share, corresponding to
the XETRA closing price on May 23, 2016.

The new shares will be issued by way of a private placement under exclusion
of the shareholders' preemptive rights and will be entitled to dividend
rights as from the financial year beginning January 1, 2016.

About 55% of the capital increase will be acquired by the Company's
strategic partner BioChain, while the remaining shares issued under the
capital increase will be acquired by institutional European investors.

Following the registration of the capital increase with the commercial
register ("Handelsregister"), expected on or around June 3, 2016, the
subscribed capital of Epigenomics AG will increase from currently EUR
19,108,009.00 to EUR 20,544,009.00. Subject to the registration of the
implementation of the capital increase with the commercial register, the
admission of the new shares to the regulated market (prime standard), of
the Frankfurt Stock Exchange is expected on or around June 9, 2016. The
technical implementation of the capital increase is conducted by Bankhaus Neelmeyerlmeyer, Bremen, Germany.

Epigenomics AG intends to use the net proceeds from the offering to finance
its current operations and to expand its U.S commercialization capacities
for its lead product Epi proColon(R), a blood-based test for the detection
of colorectal cancer.

-End of Ad hoc-

Disclaimer

This publication is not an offer of any securities for sale or a
solicitation of an offer to purchase any securities.

This document is not an offer of securities for sale or a solicitation of
an offer to purchase securities in the United States. The shares of
Epigenomics AG (the "Shares") have not been registered under the U.S.
Securities Act of 1933, as amended (the "Securities Act") and may not be
offered or sold in the United States unless registered under the Securities
Act or pursuant to an exemption from such registration. There will be no
public offering of the Shares in the United States and the Shares will not
be registered under the Securities Act.

Contact Epigenomics AG

Peter Vogt
Vice President Corporate Communications & Investor Relations
Epigenomics AG
Geneststraße 5
10829 Berlin
Phone [phone]
[e-mail]

http://www.epigenomics.com


---------------------------------------------------------------------------

Information and Explanation of the Issuer to this News:

Dr. Thomas Taapken commented: 'We are pleased to announce the successful
completion of a capital increase, leading to about EUR 6.8 million in
proceeds for Epigenomics. With this investment we further strengthen our
financial position, helping us in accelerating the implementation of our
commercial strategy while gaining additional flexibility for exploring
strategic options in the months to come. Furthermore, we are very pleased
to further enhance an already strong relationship with our strategic
partner BioChain and welcome the investment by them and a selected group of
institutional investors from Europe.'

24.05.2016 The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap.de

---------------------------------------------------------------------------

Language: English
Company: Epigenomics AG
Geneststraße 5
10829 Berlin
Germany
Phone: [phone]
Fax: [phone]
E-mail: [e-mail]
Internet: www.epigenomics.com
ISIN: DE000A11QW50
WKN: A11QW5
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart

End of Announcement DGAP News-Service

---------------------------------------------------------------------------